GlobeNewswire (Wed, 7:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,498 people get ZIOP articles and Market Currents by email alert.
Get email alerts on ZIOP »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
GlobeNewswire (May 15, 2013)
-
GlobeNewswire (May 7, 2013)
-
-
-
-
GlobeNewswire (Apr 9, 2013)
-
-
-
-
-
-
-
GlobeNewswire (Mar 26, 2013)
-
-
GlobeNewswire (Mar 18, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
GlobeNewswire (Wed, 7:00AM)
-
GlobeNewswire (May 15, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (Apr 9, 2013)
-
at MarketWatch.com (Mar 26, 2013)
-
GlobeNewswire (Mar 26, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
at CNBC.com (Feb 14, 2013)
-
GlobeNewswire (Feb 6, 2013)
-
GlobeNewswire (Jan 3, 2013)
-
GlobeNewswire (Nov 28, 2012)
-
GlobeNewswire (Nov 20, 2012)
-
GlobeNewswire (Nov 8, 2012)
ZIOP vs. ETF Alternatives
Company Description
Currently, there's no company description for ZIOP.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Friday, May 24, 12:45 PM
Midday top 10 gainers: OTT +41%. ZIOP +25%. ESMC +18%. DRAM +17%. FCEL +17%. VNDA +17%. TNP +16%. BLDP +14%. BLOX +13%. VRTA +12%.
Midday top 10 Losers: DF -51%. RNIN -29%. ETAK -17%. SHLD -14%. HIHO -14%. HGSH -12%. PLM -11%. ANF -10%. TITN -10%. ARO -10%. 4 Comments [On the Move] - Friday, May 24, 10:33 AM Ziopharm Oncology (ZIOP +39.1%) soars on huge volume. The stock is now up ~68% since Wednesday. Comment! [Healthcare, On the Move]
-
Tuesday, April 9, 9:10 AM
Premarket gainers: CLRX +13%. ZIOP +12%. RDN +5%. UNXL +5%.
Losers: OCZ -13%. JCP -7%. Comment! [On the Move] - Tuesday, April 9, 8:31 AM Ziopharm's (ZIOP +8.6%) Ad-RTS-mIL-12 DNA-based therapy has demonstrated anti-tumor effects and tolerability in mice. Ad-RTS-IL-12 is being tested in two Phase 2 studies, one for advanced melanoma and the other for breast cancer. (PR) Comment! [Healthcare, On the Move]
-
Tuesday, March 26, 12:54 PM
Midday top 10 gainers: PTEK +30%. BVX +23%. OPXA +20%. LEDS +20%. IBCP +13%. DXYN +11%. GTAT +11%. APP +11%. HGSH +9%. PGNX +9%.
Midday top 10 losers: ZIOP -62%. FUQI -17%. GMAN -16%. PGTI -14%. STSI -13%. GMXR -11%. STXS -11%. PRTS -10%. REED -10%. CSUN -8%. Comment! [On the Move] - Tuesday, March 26, 11:23 AM Threshold Pharmaceuticals (THLD +1.3%) gains on the back of Ziopharm's (ZIOP -63%) earlier announcement that it's ending Phase 3 trials of palifosfamide after it failed to meet its primary endpoint. An article posted in Seeking Alpha last Friday infers that THLD's competing drug, TH-302, although similar to palifosfamide in molecular structure, is differentiated enough in nature that there is still sufficient reason to believe it could work. Now, with ZIOP's drug out of the running, TH-302's addressable market increases significantly. The company is due to release data from its own Phase III study early next year. 1 Comment [Healthcare, On the Move]
-
Tuesday, March 26, 9:15 AM
Premarket gainers: THLD +8%. CTIC +6%.
Losers: ZIOP -62%. PLCE -6%. PATH -6%. Comment! [On the Move] - Tuesday, March 26, 7:17 AM Ziopharm Oncology (ZIOP) -59% after reporting the failure of palifosfamide in its Phase 3 trial, and saying it is pulling development of the treatment. Kudos to Adam Feurstein's source who was certain enough of the test results to short the stock last week. 3 Comments [Healthcare, On the Move]
- Friday, March 22, 9:54 AM Ziopharm Oncology (ZIOP -5.8%) opens down big after Adam Feurstein reports an oft-correct source has shorted the stock ahead of what he/she thinks will be the failure of next week's results of the palifosfamide sarcoma study. Comment! [Healthcare, On the Move]
-
Friday, March 22, 9:10 AM
Premarket gainers: HALO +23%. ANAC +18%. MU +9%. AFFY +8%. NKE +8%.
Losers: TIBX -16%. ABR -6%. ZIOP -5%. Comment! [On the Move] - Monday, March 18, 4:49 PM More on Ziopharm (ZIOP): Q4 comes in-line on revenue but misses on a per shares basis. Operating expenses rose 134% over the prior year, primarily due to an $18.7M non-cash expense associated with the issuance of approximately 3.6M shares of common stock to Intrexon as a milestone payment associated with the dosing of the first patient in its Ad-RTS IL-12 Phase 2 trial. Shares -2% AH. Comment! [Healthcare, Earnings, On the Move]
- Monday, March 18, 4:22 PM Ziopharm (ZIOP): Q4 EPS of -$0.37 misses by $0.08. Revenue of $200K beats by $30K. Shares -1.1% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Wednesday, March 13, 7:18 PM Ziopharm (ZIOP) is getting whipped about in thin after-hours trade this evening following unconfirmed reports that SAC Capital had taken a 5.2% stake in the company. After briefly popping +1.25%, the stock has since fallen back, now trading -0.9%. It's also worth noting that the company also presented at the Barclay's Healthcare Conference a few hours ago as well. (Presentation Webcast) 1 Comment [Healthcare, On the Move]
- Monday, March 11, 3:13 PM Ziopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer. Comment! [Healthcare, On the Move]
- Wednesday, February 13, 10:07 AM Ziopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which appears to have performed well in patients with metastatic soft tissue sarcoma in a Phase III trial. Ziopharm may sign a deal before the full study data is known, although the greater likelihood is after its release in March. Ziopharm's shares shot up 18% yesterday on news of the trial, and are now +2.1%. Comment! [Healthcare, On the Move]
-
Tuesday, February 12, 12:45 PM
Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move]
-
- View all 1 replies
-
-
- View all 0 replies
-
Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it. - View all 3 replies
-
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
dindin21: How did you get to $.90? That puts the value at about cash@ ~73million.
-
-
Red Acre Investments
While we wait for $ZIOP results - visit Red Acre Investments & cast your vote on which way the data will go: http://bit.ly/14k2VHo - View all 0 replies
-
Red Acre Investments
In case you're not already reading us at redacre.com - here's our take on $ZIOP: http://bit.ly/16uPEeQ - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it. - View all 3 replies
-
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
-
-
- View all 3 replies
-
dindin21: How did you get to $.90? That puts the value at about cash@ ~73million.
-
-
Scott Matusow
$ZIOP moving like I thought it would. shorts still being stubborn, they are soon to be crushed on that one. - View all 12 replies
-
-
Scott Matusow: i agree, and CHTP is a stock that might be worth the wait for the big bucks, but not anytime soon.
-
Scott Matusow
Should have an article out on $ ZIOP tomorrow. I bought some, that is my first pick, have fun - View all 1 replies
-